Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041 Jun 9, 2022
Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy May 17, 2022
Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy Apr 11, 2022
Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022 Mar 15, 2022
